PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab

PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab

Melanoma displays a rising incidence, and the mortality associated with metastatic form remains high. Monoclonal antibodies that block programmed death (PD-1) and PD Ligand 1 (PD-L1) network have revolutionized the history of metastatic disease. PD-L1 is expressed on several immune cells and can be...

Full description

Bibliographic Details
Main Authors: Leonardo Cristinziano, Luca Modestino, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Diana Giannarelli, Grazia D’Angelo, Anne Lise Ferrara, Stefania Loffredo, Gilda Varricchi, Vito Vanella, Lucia Festino, Paolo Antonio Ascierto, Maria Rosaria Galdiero
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Immunology
Subjects:
melanoma
checkpoint inhibitors
nivolumab
tumor-associated neutrophil
neutrophil plasticity
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.962669/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.962669/full

Similar Items